Oregon hosts global immunology conference featuring Providence immuno-oncology research

Immunology professionals from across the world will convene in May for the American Association of Immunologists (AAI) Immunology2022TM, the largest immunology event in the world.

The annual event will be held May 6 through 10 at the Oregon Convention Center in Portland, Oregon, and is an opportunity for the immunology community to network and hear from some of the world’s most prominent scientists. We are delighted that our researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, are among the program chairs and presenters.

Of note, Michael Gough, Ph.D., member, Integrated Therapies Laboratory, will chair the Non-Immune Therapies in Cancer block symposium, and Andrew D. Weinberg, member and Judith Ann Hartmann Endowed Chair for the Basic Immunology Laboratory, will co-chair the Society for Immunotherapy of Cancer (SITC) guest symposium.

A complete program along with event details, presentation dates and times can be found online.

Guest Symposium

Society for Immunotherapy of Cancer (SITC) Symposium

Chair and speaker: Andrew D. Weinberg, Ph.D., member, and Judith Ann Hartmann Endowed Chair, Basic Immunology Laboratory

Identifying tumor-reactive CD8+ TIL in patients with solid malignancies: clinical implications

Block Symposiums

Big Data: The Key to Unlocking Immune Mediated Mechanisms of Tumor Progression and Therapy Response

Speaker: William Redmond, Ph.D., member, Cancer Immunotherapy Laboratory

Multimodal single-cell analysis of human TILs across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapy

Non-Immune Therapies in Cancer

Chair and speaker: Michael Gough, Ph.D., member, Integrated Therapies Laboratory

Fluorescence tagging to monitor CD8 T cell recirculation from the tumor to the tumor-draining lymph node: the impact of focal radiation therapy on recirculation

Tumor Immunotherapy

Speaker: Colin Thalhofer, Ph.D., AgonOx Inc., a biotechnology affiliate of Providence

Enriching for tumor-reactive CD8 TIL (AGX148) leads to effective tumor clearance in a patient-derived xenograph model

Speaker: Thomas Duhen, Ph.D., assistant member, Anti-Cancer Immune Response Laboratory  

PD-1 and ICOS co-expression identifies tumor-reactive CD4 Th cells in human solid tumors

Poster Sessions

Abstract 63.02: Tumor resident memory CD8 T cell formation and concomitant tumor immunity is CD40L dependent and CD4 independent. M. Gough, G. Kramer, S. Bambina, A. Alice, T. Blair, T. Duhen, R. Duhen, M. Crittenden

Abstract 65.14: OX40 boosts and sustains humoral and cellular immune responses to SARS-CoV2 spike protein and RNA vaccinations. R Duhen...S Jensen...BA Fox...A Weinberg.

Abstract details are available in the AAI Events app.

About Earle A. Chiles Research Institute

The Earle A. Chiles Research Institute is a world-class research facility dedicated to discovering curative therapies for cancer patients. Our main area of investigation is cancer immunotherapy, a specialized field of study focused on harnessing the innate power of the immune system to cure cancer.

For our latest news and announcements, visit our website and follow us on Twitter, Facebook and LinkedIn.

Related stories

New study evaluates immunoradiotherapy treatment for head and neck cancer patients

Cancer Moonshot relaunch aligns with Providence initiatives to reduce cancer burden and improve health equity

Providence immunotherapy research presented at global conference

Previous Article
Baby Goat Therapy introduced at St. Joseph and Redwood Memorial Hospitals
Baby Goat Therapy introduced at St. Joseph and Redwood Memorial Hospitals

Baby Goat Therapy introduced at St. Joseph and Redwood Memorial Hospitals

Next Article
New study evaluates immunoradiotherapy treatment for head and neck cancer patients
New study evaluates immunoradiotherapy treatment for head and neck cancer patients

Investigator-initiated clinical trial at Providence Cancer Institute to evaluate the safety and efficacy of...